This week’s Research Roundup highlights cardiovascular concerns in BRCA1 and BRCA2 mutation carriers.
Jeff Meeusen, Ph.D., Co-Director of Cardiovascular Laboratory Medicine in the Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester, Minnesota, provides a clinical update on ceramides.
In this month’s “Hot Topic,” Nancy Wengenack, Ph.D., provides an overview of the current Mycobacterium chimaera outbreak and discusses what is known regarding the source of infection. In addition, she will discuss the clinical features of the disease and the recommended laboratory tests that can assist with diagnosis.
With more than 70,000 uses worldwide and policy endorsements for its use (JAMA Article), the Mayo Clinic Statin Choice Decision-Aid tool is helping patients and their clinicians have meaningful conversations about whether or not to use statins to reduce cardiovascular risk.
Jeff Meeusen, Ph.D., a clinical chemist and Co-Director of Cardiovascular Laboratory Medicine at Mayo Clinic in Rochester, recently authored an article in Clinical Laboratory News that discusses patient fasting in lipid testing. While lipids measured on fasting samples have always been the status quo, the rules might be about to change.
High-sensitivity cardiac troponin levels are strongly associated with the risk for incident heart failure. Allan Jaffe, M.D., Consultant and Chair of Mayo Clinic’s Division of Clinical Core Laboratory Services, with a joint appointment in the Division of Cardiovascular Diseases, weighs in on the topic.
This week’s Research Roundup highlights how cardiac troponin is released from injured myocardium.
Allan Jaffe, M.D., Consultant and Chair of Mayo Clinic’s Division of Clinical Core Laboratory Services, with a joint appointment in the Division of Cardiovascular Diseases, spoke with CAP Today about what a new higher-sensitivity cardiac troponin assay means from a pathology and cardiology perspective.
This week’s Research Roundup highlights global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction.
Researchers from Mayo Clinic and the Johns Hopkins University School of Medicine published an article in "JAMA Internal Medicine" outlining the elimination from clinical practice of a popular test for diagnosing heart attacks.
Sudden cardiac death and episodes of fainting and seizures from long QT syndrome are significantly lower than previously thought when patients are diagnosed and treated at a specialty center dedicated to the treatment of genetic heart rhythm diseases, according to Mayo Clinic research published in the Journal of the American College of Cardiology.
Clinical Laboratory News recently highlighted a Mayo Clinic study that shows how plasma ceramides may predict cardiovascular events in patients with or without coronary artery disease.